Cargando…

CircRNAs in anticancer drug resistance: recent advances and future potential

CircRNAs are a novel class of RNA molecules with a unique closed continuous loop structure. CircRNAs are abundant in eukaryotic cells, have unique stability and tissue specificity, and can play a biological regulatory role at various levels, such as transcriptional and posttranscriptional levels. Nu...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Tianwei, Wang, Mengwei, Jiang, Lihua, Ma, Li, Wan, Li, Chen, Qinnan, Wei, Chenchen, Wang, Zhaoxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429705/
https://www.ncbi.nlm.nih.gov/pubmed/32799866
http://dx.doi.org/10.1186/s12943-020-01240-3
_version_ 1783571301315641344
author Xu, Tianwei
Wang, Mengwei
Jiang, Lihua
Ma, Li
Wan, Li
Chen, Qinnan
Wei, Chenchen
Wang, Zhaoxia
author_facet Xu, Tianwei
Wang, Mengwei
Jiang, Lihua
Ma, Li
Wan, Li
Chen, Qinnan
Wei, Chenchen
Wang, Zhaoxia
author_sort Xu, Tianwei
collection PubMed
description CircRNAs are a novel class of RNA molecules with a unique closed continuous loop structure. CircRNAs are abundant in eukaryotic cells, have unique stability and tissue specificity, and can play a biological regulatory role at various levels, such as transcriptional and posttranscriptional levels. Numerous studies have indicated that circRNAs serve a crucial purpose in cancer biology. CircRNAs regulate tumor behavioral phenotypes such as proliferation and migration through various molecular mechanisms, such as miRNA sponging, transcriptional regulation, and protein interaction. Recently, several reports have demonstrated that they are also deeply involved in resistance to anticancer drugs, from traditional chemotherapeutic drugs to targeted and immunotherapeutic drugs. This review is the first to summarize the latest research on circRNAs in anticancer drug resistance based on drug classification and to discuss their potential clinical applications.
format Online
Article
Text
id pubmed-7429705
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74297052020-08-18 CircRNAs in anticancer drug resistance: recent advances and future potential Xu, Tianwei Wang, Mengwei Jiang, Lihua Ma, Li Wan, Li Chen, Qinnan Wei, Chenchen Wang, Zhaoxia Mol Cancer Review CircRNAs are a novel class of RNA molecules with a unique closed continuous loop structure. CircRNAs are abundant in eukaryotic cells, have unique stability and tissue specificity, and can play a biological regulatory role at various levels, such as transcriptional and posttranscriptional levels. Numerous studies have indicated that circRNAs serve a crucial purpose in cancer biology. CircRNAs regulate tumor behavioral phenotypes such as proliferation and migration through various molecular mechanisms, such as miRNA sponging, transcriptional regulation, and protein interaction. Recently, several reports have demonstrated that they are also deeply involved in resistance to anticancer drugs, from traditional chemotherapeutic drugs to targeted and immunotherapeutic drugs. This review is the first to summarize the latest research on circRNAs in anticancer drug resistance based on drug classification and to discuss their potential clinical applications. BioMed Central 2020-08-17 /pmc/articles/PMC7429705/ /pubmed/32799866 http://dx.doi.org/10.1186/s12943-020-01240-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Xu, Tianwei
Wang, Mengwei
Jiang, Lihua
Ma, Li
Wan, Li
Chen, Qinnan
Wei, Chenchen
Wang, Zhaoxia
CircRNAs in anticancer drug resistance: recent advances and future potential
title CircRNAs in anticancer drug resistance: recent advances and future potential
title_full CircRNAs in anticancer drug resistance: recent advances and future potential
title_fullStr CircRNAs in anticancer drug resistance: recent advances and future potential
title_full_unstemmed CircRNAs in anticancer drug resistance: recent advances and future potential
title_short CircRNAs in anticancer drug resistance: recent advances and future potential
title_sort circrnas in anticancer drug resistance: recent advances and future potential
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429705/
https://www.ncbi.nlm.nih.gov/pubmed/32799866
http://dx.doi.org/10.1186/s12943-020-01240-3
work_keys_str_mv AT xutianwei circrnasinanticancerdrugresistancerecentadvancesandfuturepotential
AT wangmengwei circrnasinanticancerdrugresistancerecentadvancesandfuturepotential
AT jianglihua circrnasinanticancerdrugresistancerecentadvancesandfuturepotential
AT mali circrnasinanticancerdrugresistancerecentadvancesandfuturepotential
AT wanli circrnasinanticancerdrugresistancerecentadvancesandfuturepotential
AT chenqinnan circrnasinanticancerdrugresistancerecentadvancesandfuturepotential
AT weichenchen circrnasinanticancerdrugresistancerecentadvancesandfuturepotential
AT wangzhaoxia circrnasinanticancerdrugresistancerecentadvancesandfuturepotential